LPGO — Lipigon Pharmaceuticals AB Share News
0.000.00%
Last trade - 00:00- SEK1.64m
- -SEK8.58m
Brief: Lipigon Pharmaceuticals Q3 Operating Loss Narrows To SEK 4.9 Mln
Brief: Lipigon Secures US Patent For Treatment Of Cardiometabolic Disease
Brief: Lipigon Pharmaceuticals Q2 Operating Profit Up At SEK 7.1 Mln
Brief: Lipigon Pharmaceuticals Receives Grant From Vinnova
Brief: Lipigon Announces Development, License Agreement For Drug Candidate Lipisense
Brief: Lipigon Pharmaceuticals Announces Notice Of Allowance For Patent Application
Brief: Lipigon Pharmaceuticals Q1 Operating Loss Narrows To SEK 6.8 Mln
Brief: Lipigon Pharmaceuticals Carries Out Directed Issue Of Units
Brief: Lipigon Pharmaceuticals Appoints Hugo Petit As New CFO
Brief: Lipigon Pharmaceuticals Rights Issue Generates Proceeds Of SEK 29.3 Mln
Brief: Lipigon Pharmaceuticals Gets Additional Subscription Commitment, Top Guarantee For Rights Issue
Brief: Lipigon Pharmaceuticals Decides On Rights Issue Of Units Of About SEK 35.4 Mln
Brief: Lipigon Pharmaceuticals Q4 Oper Loss Narrows To SEK 9.2 Million
Brief: Lipigon Pharmaceuticals Q2 Operating Loss Narrows To SEK 6.8 Million
Brief: Lipigon Announces Positive Top-Line Data From Phase I Clinical Study Of Lipisense
Brief: Lipigon Pharmaceuticals Q2 Operating Loss Widens To SEK 12.7 Mln
Brief: Lipigon Pharmaceuticals To Receive SEK 22.6 Mln Through Rights Issue
Brief: Lipigon Pharmaceuticals Gets Proceeds Of SEK 22.6 Million Through Rights Issue
Brief: Lipigon Pharmaceuticals' Nomination Committee Proposes Lars Öhman As New Chairman